Keeps getting better. Report on CC from YMB - Pfizer has continued AND expanded collaboration in cancer - Concluded a $37 million licensing agreement with Merck - Glaxo initiated a Phase III trial - Sanofi Aventis completed a Phase I trial - Granted to a license to Dynovax - Acquired some molecules from 3M - Expanded to auto-immune diseases with a new molecule
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.